Intensity-modulated radiation therapy for anal cancer

ONCOLOGY

Volumn 23, Issue 12, 2009, Pages

  Czito, Brian G ^a   Pepek, Joseph M ^a   Meyer, Jeffrey J ^b   Yoo, Sua ^a   Willett, Christopher G ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOMYCIN; OXALIPLATIN;

ANUS CANCER; BLOOD TOXICITY; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICAL PRACTICE; MORBIDITY; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 72449120438     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Boman BM, Moertel CG, OConnell MJ, et al: Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 54:114-125, 1984.
2. Czito BG, Willett CG: Current management of anal canal cancer. Curr Oncol Rep 11:186-192, 2009.
3. Nigro ND, Vaitkevicius VK, Considine B Jr.: Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 17:354-356, 1974.
4. Buroker TR, Nigro N, Bradley G, et al: Combined therapy for cancer of the anal canal: A follow-up report. Dis Colon Rectum 20:677-678, 1977. (Pubitemid 8248303)
5. Michaelson RA, Magill GB, Quan SH, et al: Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. Cancer 51:390-395, 1983. (Pubitemid 13185364)
6. Nigro ND, Seydel HG, Considine B, et al: Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51:1826-1829, 1983.
7. Leichman L, Nigro N, Vaitkevicius VK, et al.: Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 78:211-215, 1985. (Pubitemid 15162919)
8. Meeker WR Jr, Sickle-Santanello BJ, Philpott G, Kenady D, et al: Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal. Cancer 57:525-529, 1986. (Pubitemid 16164604)
9. UK Co-ordinating Committee on Cancer Research: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. Lancet 348:1049-1054, 1996.
10. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14:2527-2539, 1996. (Pubitemid 26300120)
11. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997. (Pubitemid 27209535)
12. Ajani JA, Winter KA, Gunderson LL, et al: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 299:1914-1921, 2008.
13. James R, Wan S, Glynne-Jones R, et al: A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5fu in squamous cell carcinoma of the anus (ACT II) (abstract LBA4009). J Clin Oncol 27(15S):170s, 2009.
14. Bortfeld T, Boyer AL, Schlegel W, et al: Realization and verification of three-dimensional conformal radiotherapy with modulated fields. Int J Radiat Oncol Biol Phys 30:899-908, 1994. (Pubitemid 24355942)
15. Burman C, Chui CS, Kutcher G, et al: Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: A strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 39:863-873, 1997. (Pubitemid 27486075)
16. Stein J, Bortfeld T, Dorschel B, et al: Dynamic x-ray compensation for conformal radiotherapy by means of multi-leaf collimation. Radiother Oncol 32:163-173, 1994. (Pubitemid 24270738)
17. Kachnic L, Winter K, Myerson R, et al: RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouricil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal (abstract 10). Int J Radiol Oncol Bio Phys 75:S5, 2009.
18. Myerson RJ, Garofalo MC, El Naqa I, et al: Elective clinical target volumes for conformal therapy in anorectal cancer: A radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74:824-830, 2009.
19. Hoffman R, Welton M, Klencke B, et al: The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Rad Oncol Bio Phys 44:127-131, 1999. (Pubitemid 29186199)
20. Trautmann TG, Zuger JH: Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 7:309-313, 2005.
21. Cotter SE, Grigsby PW, Siegel BA, et al: FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 65:720-725, 2006.
22. Winton E, Heriot AG, Ng M, et al: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 100:693-700, 2009.
23. Anderson C, Koshy M, Staley C, et al: PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 69:155-162, 2007. (Pubitemid 47247507)
24. Nguyen BT, Joon DL, Khoo V, et al: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 87:376-382, 2008.
25. Mai SK, Welzel G, Hermann B, et al: Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol 185:254-259, 2009.
26. Schwarz JK, Siegel BA, Dehdashti F, et al: Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 71:180-186, 2008.
27. Konski A, Garcia M Jr, John M, et al: Evaluation of planned treatment breaks during radiation therapy for anal cancer: Update of RTOG 92-08. Int J Radiat Oncol Biol Phys 72:114-118, 2008.
28. Roohipour R, Patil S, Goodman KA, et al: Squamous-cell carcinoma of the anal canal: Predictors of treatment outcome. Dis Colon Rectum 51:147-153, 2008.
29. Constantinou EC, Daly W, Fung CY, et al: Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 39:651-657, 1997. (Pubitemid 27441432)
30. Huang K, Haas-Kogan D, Weinberg V, et al: Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 13:895-900, 2007. (Pubitemid 46470300)
31. Ben-Josef E, Moughan J, Ajani J, et al: The impact of overall treatment time on survival and local control in anal cancer patients: A pooled data analysis of RTOG trials 8704 and 9811 (abstract 55). Int J Rad Oncol Bio Phys 75:S26, 2009.
32. Widder J, Kastenberger R, Fercher E, et al: Radiation dose associated with local control in advanced anal cancer: Retrospective analysis of 129 patients. Radiother Oncol 87:367-375, 2008.
33. Hughes LL, Rich TA, Delclos L, et al: Radiotherapy for anal cancer: Experience from 1979-1987. Int J Radiat Oncol Biol Phys 17:1153-1160, 1989.
34. Milano MT, Jani AB, Farrey KJ, et al: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63:354-361, 2005. (Pubitemid 41317151)
35. Pepek J, Willett C, Clough R, et al: Intensity-modulated radiation therapy (IMRT) for anal cancer: The Duke University experience (abstract 2191). Int J Rad Oncol Bio Phys 75:S267, 2009.
36. Mundt AJ, Lujan AE, Rotmensch J, et al: Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52:1330-1337, 2002. (Pubitemid 34296492)
37. Mundt AJ, Mell LK, Roeske JC: Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56:1354-1360, 2003. (Pubitemid 36842887)
38. Ashman JB, Zelefsky MJ, Hunt MS, et al: Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63:765-771, 2005. (Pubitemid 41400064)
39. Salama JK, Mell LK, Schomas DA, et al: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience. J Clin Oncol 25:4581-4586, 2007. (Pubitemid 350035316)
40. Brixey CJ, Roeske JC, Lujan AE, et al: Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54:1388-1396, 2002. (Pubitemid 35380039)
41. Mell LK, Kochanski JD, Roeske JC, et al: Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 66:1356-1365, 2006.
42. Mell LK, Schomas DA, Salama JK, et al: Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70:1431-1437, 2008.